๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX ยท Real-Time Price ยท USD
0.6138
-0.0180 (-2.85%)
At close: Nov 19, 2026, 4:00 PM EST
0.6260
+0.0122 (1.99%)
After-hours: Nov 19, 2026, 7:45 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

MGX-001 uses CRISPR-mediated factor VIII integration, with durable NHP activity and dose-dependent preclinical results. INTEGR8 is planned to start in H1 2027, with initial safety and efficacy data expected in H2; cash runway extends through 2028.

Maury Raycroft
Analyst, Jefferies

Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the team from Metagenomi. We've got the CEO, Jian Irish, and the CFO, Pamela Wapnick. Thanks so much for joining us today. Metagenomi is going to show some slides, and then we'll do a fireside chat format.

Jian Irish
CEO, Metagenomi Therapeutics

Okay. Thank you very much, Maury. I'm pleased to be here. We'll start with a short presentation, show our data. Metagenomi is an in vivo CRISPR gene editing company, so we capitalize on proprietary technologies to create potentially curative genetic medicines. We recently cleared IND for our leader program, MGX-001, with a novel approach for hemophilia A. We're focused on initiating the phase I/II study in the first half of next year. This is our forward-looking statement. Let me begin by briefly telling you about hemophilia A. Children with severe hemophilia A today still grow up expecting joint damage from the cumulative bleeding disorder, despite the real progress in managing the disease. The patient population is significant as a rare disease. There are about 500,000 patients worldwide and 25,000 patients in the U.S.

One-third of patients have no family history, so a newly diagnosed patient and his family would have to spend a long time learning to manage bleeding and treatment burdens that would last for the rest of their life. We plan to initiate INTEGR8, a phase I/II trial in adult patients with moderately severe to severe hemophilia A, with the future potential to expand it to children. I want to tell you the totality of our preclinical data is extremely convincing, supports a highly differentiated profile with the potential to set a new standard of care. Now let's talk about the standard of care landscape. Factor VIII replacement and non-factor VIII mimetic treatments require lifelong repeated dosing, and it is not curative, still has a risk of breakthrough bleeding. Those treatments also come with extraordinary cost. What you're seeing here are just the treatment costs.

The recent trial with the AAV gene therapy for one-time treatment was initially promising, but experienced limited uptake in the market, mostly attributed to unpredictable and declining factor VIII activity over time. Of course, the prolonged steroid use also presented a treatment challenge. We see the opportunity to develop a genuine, durable, one-time treatment to address the root genetic cause and provide a long-term benefit for both adults and especially children, who have the most to benefit from a one-time treatment. Our gene editing approach is structurally different from the prior AAV gene therapy, and rather than remain episomal, the factor VIII gene integrates directly into the chromosomal, targeting the stable and active albumin promoter.

We deliver a promoter-less factor VIII DNA template, I should say, we deliver a factor VIII DNA template in a promoter-less AAV cassette, and we also deliver the LNP encapsulate the mRNA that encodes our proprietary CRISPR nuclease, MG29-1, and the guide. That integrates the factor VIII gene site-specifically at the albumin locus to drive sustained factor VIII production with durable and high expression with very low gene integration frequency. Now I want to show you some data from our preclinical study. Durability is the most important for one-time treatment, and we consider this very early in our development, and early study done in the NHP model, we used a research version of a pre-development candidate. We saw the rise of the factor VIII to the peak level activity within two weeks and remained stable through the end of the study up to 19 months.

Most importantly is the factor VIII activity is correlated to the integration frequency, and we also saw stable factor VIII expression was achieved in the study that animals' liver size doubled over the duration of the study, which is exactly what you'd expect given our mechanism, since the editing becomes a permanent part of a genome, rather than episomal expression that could fade over the time. The second important study was the dose range-finding study. We are extremely pleased by the clear dose dependency in this study, and especially with the factor VIII activity level reaching the normal physiological range of 50 IU/dL - 150 IU/dL in the targeted group two and five, shown in the dark blue. That is our target range.

Now, if you consider severe hemophilia patients only have less than 1% IU/dL factor VIII level, this could be a significantly drastic clinical meaningful shift. Also important is the animals in the study did not exceed the ceiling expression level 150 IU/dL that could increase the risks of thrombosis. Even at the highest dose levels, and we see this as a potential wide safety margin in our design. Then you also look at the minimal dose in group cohort, group one, we've already reached 10 IU/dL- 25 IU/dL. That is the level of the current mimetic standard of care would achieve the equivalency. Just to remember, mimetics don't express factor VIII, but it's the equivalency of the activity level.

I want to point out the AAV dose level we use in this study that achieved normal range factor VIII activity level is very low. It's roughly, it's more than actually tenfold below the previous AAV gene therapy, which we believe is an important safety factor in clinic. Now, we have the IND clearance that enables us initiate our phase I/II clinical trial in the U.S., and we plan to submit applications in additional regulatory jurisdictions to support our global trial. We plan, we're focused on initiating our study in the first half of next year, expected to share initial clinical data in the second half. Finally, I want to leave this with you as we consider the follow-on programs. The MGX-001 gene integration approach by delivering the factor VIII template with AAV and CRISPR gene editing cargo in the LNP is a modular system.

We can replace the therapeutic transgene DNA template to expand into other protein deficiencies diseases and expect to gain development efficiency. With that, I am happy to take any questions.

Maury Raycroft
Analyst, Jefferies

Great. Thanks, Jian. That was a nice intro to the company and where you are at, and congrats on the IND clearance. Maybe just starting with just kind of one of the common things that we hear is that for hemophilia A, that is a well-served disease setting where there are a lot of great treatments out there. As you engage with the hemophilia community, what specific feedback have you gotten, and how has that informed your clinical development strategy?

Jian Irish
CEO, Metagenomi Therapeutics

That is a very important question. We have engaged with the hemophilia community very early and used the feedback to guide our development path. What we have learned is it is very clear the current standard of care is just manage the diseases but not address the genetic root causes. Patients still have to experience breakthrough bleedings and restricted lifestyles and surgery and injury risks. Diseases always on their mind, right? They have to adjust their lifestyle to manage the diseases. We also learned from the hematologists that there is this undetectable microbleeds that could lead to arthropathy. Even the best physicians with the best treatment, they still have to advise the patients and/or the parents of the patients that they cannot eliminate the arthropathy in the late in the life.

Factor VIII level has the half-life, so that it goes peaks and troughs, and mimetics really do not express factor VIII. The microbleeds in risk in the late life is still not clear. You also saw, in addition to treatment burdens, there is cost burdens and the burdens of dealing with reimbursement. From patients' perspective, this is truly a medical needs to them, and our goal is to deliver one-time treatment to normalize the factor VIII levels and really giving the disease-free mind to the patients.

Maury Raycroft
Analyst, Jefferies

That makes sense. You basically talked about one patient population opportunity right there, where those patients would likely go for a one-time treatment, older patients that have the microbleeds, which is interesting. Now that the IND is cleared, can you give us a sense of the remaining operational steps to first dosing and how you're thinking about timing there? What first patient dose window would keep you comfortable with a meaningful update in second half of 2027?

Jian Irish
CEO, Metagenomi Therapeutics

First, just to talk about the study. The phase I/II study we named as INTEGR8 clinical trial is open-label, single-arm, and we're going to use multiple centers, including international centers for this study. Then with dose escalation followed by dose expansion once we reach the target efficacy level. Our target efficacy level is the normal physiological level, it's at 50%-150% . As I said, severe patients only have less than 1%, so it is a really significant shift for the patients. The second is we have got IND in the U.S., so multi-center, including outside of U.S. treatment centers. We work with the major centers that have experience in the gene therapy for hemophilia treatments in the past. Also important is those sites, including, of course, Europe as well as other countries that advanced the standard of care is not available.

I also want to just characterize this as important of our learning from the community is that typically for hemophilia patients, the hematologists, they follow the patients for their lifetime. So they know the patients, they know the patient population, who's looking for when time treat them. Especially the patients who still in their active life phase has the most strong desire. Of course, we have clinical supply ready, and it's all released, ready to go. So we're really focusing on to get the study initiated the first half of next year.

Maury Raycroft
Analyst, Jefferies

Got it. That's all helpful. I guess for getting to data in the second half of next year, maybe talk about what that could look like, how many patients you could have in that data update.

Jian Irish
CEO, Metagenomi Therapeutics

Of course, we start with the lower dose, but with biological activities. We will escalate. Another important point I want to mention to you is, on the early slide, you saw the rise of factor VIII activity within two weeks is really important for us to take that into the consideration. For the initial study, we are not only going to observe the safety signals, but also activity levels. In terms of a number of patients per cohorts, we will follow the standard phase I until we reach the target efficacy level and for expansion. We do expect to see activities in the initial patient groups and make decisions to escalate to our target and efficacy.

Maury Raycroft
Analyst, Jefferies

Got it. Just clarifying, for the LNP versus AAV, would you increase the dose of the LNP and keep the AAV dose constant, or?

Jian Irish
CEO, Metagenomi Therapeutics

Yeah, the dose range of findings study was really clear. When we fixed the AAV dose, we just saw a linear correlation with the efficacy as we escalated the LNP. We plan to follow that approach. What is really nice about this is the AAV dose is low, as I talked about, but even with LNP, and we saw the activity level is at the standard of care level at very low LNP dose, like 0.2 mg. We do expect we will get really good signals on not only safety and activities at the beginning. This also simplify the clinical trial design.

Maury Raycroft
Analyst, Jefferies

Right. Yeah, makes sense. How do you view the overall safety profile, and do you need to implement any unique risk mitigation measures for the study?

Jian Irish
CEO, Metagenomi Therapeutics

The answer is no. Our preclinical study showed really good, a favorable clinical, the safety profile. We only saw mild, the transient, the liver enzyme elevation for the targeted dose cohorts. We will implement a short course of premedication before the LNP dose, but other than that, we do not expect. We are going to see safety signals from the phase I study initial patients. Of course, we are going to monitor closely, and if there is a need for adjustment, we will adapt to that.

Maury Raycroft
Analyst, Jefferies

Okay.

Jian Irish
CEO, Metagenomi Therapeutics

It is really good as we are working with the hematologists who are experienced with gene therapy. It will be really good collaboration.

Maury Raycroft
Analyst, Jefferies

Is that premedication regimen, is that already determined, or are there still some variables there? Is it?

Jian Irish
CEO, Metagenomi Therapeutics

We agree with the FDA.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. Is there anything more you can say about what it is? Is it steroids or?

Jian Irish
CEO, Metagenomi Therapeutics

It would be a very. Yeah, it would be a steroid course. It's got very simple and nothing unfamiliar from what you have seen in the CRISPR.

Maury Raycroft
Analyst, Jefferies

Got it.

Pamela Wapnick
CFO, Metagenomi Therapeutics

Yeah, a short steroid course.

Jian Irish
CEO, Metagenomi Therapeutics

Yeah.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. Presumably, dosing is going to be staggered between patients in the initial cohorts. What is FDA's guidance for a safety observation window before dosing the next patient, and when could you get to non-staggered or concurrent dosing?

Jian Irish
CEO, Metagenomi Therapeutics

Yeah. I want to say the phase I study has observation of safety and activities, right? If we see the activities start to rise within two weeks, we will see the safety and the activities almost at the same time, and then we make decisions on the patient enrollment based upon what we see of the both elements. Because we started at a very low dose, I think we feel pretty good about the balance, the two arms as we escalate the dose cohorts. One more thing I think it's important to remember is we already set up our targeted dose at the normal physiological range. So we'll be efficient as we escalate towards that dose level, so long as we don't see concerning safety signals.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. As you're going to higher doses, we can assume that you've got safety, but you're probably also seeing efficacy as well. I guess, once you hit efficacy, then does that lead to an expansion or?

Jian Irish
CEO, Metagenomi Therapeutics

Exactly.

Maury Raycroft
Analyst, Jefferies

Yeah. Okay.

Pamela Wapnick
CFO, Metagenomi Therapeutics

But Maury, just to clarify, we expect to see efficacy even with our initial dose.

Maury Raycroft
Analyst, Jefferies

With the initial dose.

Pamela Wapnick
CFO, Metagenomi Therapeutics

Right. And that could be at the level that is comparable to the current standard of care when you think about what we saw in non-human primates. So if you just did a one-to-one translation from non-human primates to humans, you'd be at kind of the current standard of care level.

Maury Raycroft
Analyst, Jefferies

Got it. Makes sense. And talk about your LNP. How differentiated is your LNP from clinically validated formulations? Are the key lipids proprietary or licensed, and is there direct human exposure to the same components?

Jian Irish
CEO, Metagenomi Therapeutics

We use a licensed lipid that adapted to our CRISPR gene editing cargo. Every gene cargo is different. This is, we have already shown the effectiveness of that. The LNP, the lipid has been used in the clinic, and that is ahead of us.

Maury Raycroft
Analyst, Jefferies

Got it. Maybe set the stage for what the first data update is going to look like. What benchmarks are going to define a positive outcome for you? Is it primarily the biomarker, or could we also see some functional improvement measures as well?

Jian Irish
CEO, Metagenomi Therapeutics

Absolutely. I think we touched upon in the early points where we will see activities. I think what Pam made a point is important, and just look at all the CRISPR gene editing programs, and we see the translation from animal models to human is highly efficient, and the efficacy is looking better than the doses used in the animal. So, we are already seeing the low dose activities at low dose. We think that translation will be very key for us to watch out.

Maury Raycroft
Analyst, Jefferies

Got it. What minimum percent editing efficiency do you predict you will need to achieve for durable therapeutic benefit, and will you do any exploratory biopsies to assess editing efficiency?

Jian Irish
CEO, Metagenomi Therapeutics

I want to just make a distinction. I make sure I understand your question, because our durability is driven by the mechanism of action. We're not intend to drive high activities then let it drop.

Maury Raycroft
Analyst, Jefferies

Right.

Jian Irish
CEO, Metagenomi Therapeutics

We tested this in the growing juvenile monkeys in the NHP study. We also have done study to see the dividing cells will continue to have the stable factor VIII expression. That is the most important for us. Once again, we're targeting the normal physiological range, and we've shown the durability data in the NHP that is as good as everybody could have hoped for. We, of course, we're going to show some additional data later in our ASH oral presentation in December. But in terms of a biopsy, we use the standard protocol, which is optional for hemophilia treatments.

Maury Raycroft
Analyst, Jefferies

Okay. You could potentially get biopsies from some patients then?

Jian Irish
CEO, Metagenomi Therapeutics

Yeah, it's really up to the patient and the physicians.

Maury Raycroft
Analyst, Jefferies

But for like an editing efficiency percentage, is there something on that you're commenting on what the minimum amount of editing efficiency you'd want to see?

Jian Irish
CEO, Metagenomi Therapeutics

Yeah. The editing efficiency, yes. So once again, it's a gene insertion, so what we measure with the data you have shown is the activity is really correlated in the factor VIII integration, and the integration is very, very low. So, as we think about that, the editing in the term is more than just the CRISPR. You do the editing in one step, that's done. So we have the integration. So we're measuring the outcome of the integration. What we have learned is the activity from the integration and the translation is always correlated. As we gain more sample datas, we just get a more affirmed understanding of the translation, and we hope that's going to translate in human as well. Based upon mechanism of action, we really feel that's going to work in the way. Yeah.

Maury Raycroft
Analyst, Jefferies

Got it.

Jian Irish
CEO, Metagenomi Therapeutics

As we have shown.

Maury Raycroft
Analyst, Jefferies

Yeah. Yeah, it makes sense, which we see that with other gene editing programs too that are in vivo in the liver. You see the non-human primate editing translate to humans pretty directly.

Jian Irish
CEO, Metagenomi Therapeutics

Yeah.

Maury Raycroft
Analyst, Jefferies

You are pretty confident in that relationship between the editing and the factor VIII expression.

Jian Irish
CEO, Metagenomi Therapeutics

That is correct, yes.

Maury Raycroft
Analyst, Jefferies

You mentioned the ASH data that you are going to have in December. Your prior NHP data showed strong factor VIII activity, but some animal-to-animal variability. Do you understand the source of that variability, and what evidence gives you confidence the product entering the clinic will deliver more consistent expression?

Jian Irish
CEO, Metagenomi Therapeutics

Yeah. The two sets of data I have shown you today have shown, like, the range has been tightened over our development path, right? The first study we have done was the research material, and you saw more variability, but as we went on to the dose range-defining studies, the range getting tighter and tighter. In fact, the range we are targeting, 50 IU/dL- 150 IU/dL , is pretty broad range, whereas we are showing the animals within 30 IU/dL. That is as good as you can get. As we gain more samples, as we eventually will show more data at ASH, we just see that range getting tighter and tighter in reflecting the mechanism.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. Is there more you can share on 001 timelines and strategy that can help investors better frame the investment thesis? What is the most likely registrational path, and when do you get registration data in-house?

Jian Irish
CEO, Metagenomi Therapeutics

Once again, I want to say the factor VIII expression kinetics is very different from the episomal gene editing, episomal gene therapy previously we have seen. It is very distinctive. We see quick onset in factor VIII activity, and it remains stable. Once we see the initial patient data and showing that pattern, I think will really give us opportunities to engage the regulatory and have conversations on the further development path for the next phase.

Maury Raycroft
Analyst, Jefferies

That makes sense. That is basically the gating factor as far as timing of that goes. You are not saying a whole lot, but is it fair to assume that it could be around the second half 2027 data?

Jian Irish
CEO, Metagenomi Therapeutics

I think the initial patients are going to tell us a lot.

Maury Raycroft
Analyst, Jefferies

Yeah.

Jian Irish
CEO, Metagenomi Therapeutics

Yeah.

Maury Raycroft
Analyst, Jefferies

That's fair. Also, briefly wanted to ask, in your Ionis partnership in place, you've disclosed three or four targets as part of wave one, including ATTR and AGT, most recently APOC3 for sHTG. What's the status of these programs and anything more that you can say on timelines at this point?

Jian Irish
CEO, Metagenomi Therapeutics

Yeah. We want Pam to.

Pamela Wapnick
CFO, Metagenomi Therapeutics

Yeah. So I'll maybe field that one for you, Maury. So, we are really pleased with our relationship with Ionis. As you mentioned, there are four targets in the collaboration, and three of them have been named. One of them is not named. In terms of the original agreement with Ionis, it was for an $80 million upfront, and we had two options to opt in. We do have to look to Ionis for any further data that we can release about those programs. So, for example, a declaration of a development candidate is solely a decision of Ionis.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. Maybe just briefly talk about the distinct nuclease families you've identified and characterized to date, and how many are actively being developed for therapeutic or partnership potential?

Jian Irish
CEO, Metagenomi Therapeutics

Yeah. You've just seen the first case that we applied 29-1 to this study. In fact, it's really uniquely strong, this nuclease, that we saw no off-target editing, no translocations. It's very clean gene editing profiles. We also, of course, we have a vast library of technologies in the background, and we are going to continue to pursue additional therapeutic programs with the gene integration platform and continue to expand our collaboration opportunities for other gene editing technologies, whether it's knockdown, whether it's insertion, whether it's multiplex editing or correction, or compact nucleases. It's all in our toolbox for the collaboration.

Maury Raycroft
Analyst, Jefferies

Got it. We're out of time. Maybe to close out, if you want to highlight your cash runway assumptions and key catalysts ahead for the next 6- 12 months.

Pamela Wapnick
CFO, Metagenomi Therapeutics

Yeah, sure. So, at the end of September, we had about $102 million on the balance sheet, and that was sufficient for a runway through 2028. The key point being that in 2027, we anticipate some very significant milestones around our INTEGR8 clinical trial. That includes the initiation of the clinical trial in the first half and the initial clinical readout in the second half. That clinical readout, as we've said, will include efficacy as well as safety and tolerability. We've mentioned that we're very excited to be on the podium at ASH. I'll just close by saying that in a landscape with no cure for hemophilia A, we believe MGX-001 has the potential to provide long-term benefit for both adults and children with hemophilia, and to potentially change the standard of care.

Maury Raycroft
Analyst, Jefferies

Got it. Jian, Pam, thanks so much for joining us today.

Jian Irish
CEO, Metagenomi Therapeutics

Thank you very much, Maury.